Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Abstract Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cheng-Hsun Ho, Hung-Wen Tsai, Chen-Yeh Lee, Li-Juan Huang, Rong-Nan Chien, I-Chin Wu, Yen-Cheng Chiu, Wen-Chun Liu, Pin-Nan Cheng, Ting-Tsung Chang, Shu-Hui Chen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/cab602e9ccd94b56905ddf1a5be924e7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:cab602e9ccd94b56905ddf1a5be924e7
record_format dspace
spelling oai:doaj.org-article:cab602e9ccd94b56905ddf1a5be924e72021-12-02T11:40:59ZFavorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG10.1038/s41598-017-02158-52045-2322https://doaj.org/article/cab602e9ccd94b56905ddf1a5be924e72017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02158-5https://doaj.org/toc/2045-2322Abstract Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835–5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011–4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.Cheng-Hsun HoHung-Wen TsaiChen-Yeh LeeLi-Juan HuangRong-Nan ChienI-Chin WuYen-Cheng ChiuWen-Chun LiuPin-Nan ChengTing-Tsung ChangShu-Hui ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Cheng-Hsun Ho
Hung-Wen Tsai
Chen-Yeh Lee
Li-Juan Huang
Rong-Nan Chien
I-Chin Wu
Yen-Cheng Chiu
Wen-Chun Liu
Pin-Nan Cheng
Ting-Tsung Chang
Shu-Hui Chen
Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
description Abstract Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835–5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011–4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.
format article
author Cheng-Hsun Ho
Hung-Wen Tsai
Chen-Yeh Lee
Li-Juan Huang
Rong-Nan Chien
I-Chin Wu
Yen-Cheng Chiu
Wen-Chun Liu
Pin-Nan Cheng
Ting-Tsung Chang
Shu-Hui Chen
author_facet Cheng-Hsun Ho
Hung-Wen Tsai
Chen-Yeh Lee
Li-Juan Huang
Rong-Nan Chien
I-Chin Wu
Yen-Cheng Chiu
Wen-Chun Liu
Pin-Nan Cheng
Ting-Tsung Chang
Shu-Hui Chen
author_sort Cheng-Hsun Ho
title Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
title_short Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
title_full Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
title_fullStr Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
title_full_unstemmed Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
title_sort favorable response to long-term nucleos(t)ide analogue therapy in hbeag-positive patients with high serum fucosyl-agalactosyl igg
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/cab602e9ccd94b56905ddf1a5be924e7
work_keys_str_mv AT chenghsunho favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT hungwentsai favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT chenyehlee favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT lijuanhuang favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT rongnanchien favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT ichinwu favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT yenchengchiu favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT wenchunliu favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT pinnancheng favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT tingtsungchang favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
AT shuhuichen favorableresponsetolongtermnucleostideanaloguetherapyinhbeagpositivepatientswithhighserumfucosylagalactosyligg
_version_ 1718395485328244736

Ejemplares similares